Therapeutics

Seeking innovative breakthroughs with the power to change therapeutic paradigms

$asset->title

We invest in novel science seeking breakthroughs that address critical unmet medical needs, have the potential to change the practice of medicine whilst generating attractive investor returns.

We are venture focused and make initial investments from seed capital through early clinical development stages of truly innovative medicines and platform technologies. We have a long history of building high value, successful new companies developing transformational new medicines and bringing drugs from discovery to market.

SV can transform early science into leading companies and employs a company creation approach to biotech investing with many of SV portfolio companies being created in house.

SV invests in talented innovators and strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.

Contact our Therapeutics Team

Our Therapeutics Funds

Our investments have led to drugs that have changed lives

  • LynparzaFirst FDA approved cancer therapy for patients with a BRCA gene mutation
  • MacugenFirst FDA approved therapy to control vision loss in patients with wet age-related macular degeneration
  • EntyvioFirst FDA approved treatment for ulcerative colitis & Crohn’s disease specifically targeting gut inflammation
  • BlincytoFirst FDA approved bi-specific T-cell engager (BiTE) cancer immunotherapy

Advancing Medicine

Our team of entrepreneurs and investors have supported the generation, development, and application of cutting-edge technologies and scientific discoveries that have advanced medicine, including:

  • CRISPR technology
  • Biological dark matter
  • Bicyclic peptides
  • VEGF inhibition
  • Tumor-activated immunotherapies
  • Natural killer cell engineering
  • Lentiviral-based gene therapy
  • Aptamer selection (SELEX)
  • Switch pocket kinase inhibition
  • Myeloid cell tuning
  • Immunometabolism
  • PARP inhibition
  • Treg targeting
  • AI supported drug discovery
  • Yeast surface display

Investment Team


Operating Executives


Finance & Operations


Therapeutics Portfolio

Active Investments


Exited Investments (M&A, IPO & Recapitalization)


Therapeutics News

Investing in Women Code Logo
PROUD SIGNATORIES

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.